H.C. Wainwright Downgrades Rapt Therapeutics (RAPT) to Neutral

H.C. Wainwright analyst Emily Bodnar downgraded Rapt Therapeutics (NASDAQ: RAPT) from Buy to Neutral with a price target of $58.00.

For an analyst ratings summary and ratings history on Rapt Therapeutics click here. For more ratings news on Rapt Therapeutics click here.

Shares of Rapt Therapeutics closed at $35.10 yesterday.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• Analyst gives SpaceX a rare Sell rating citing execution risks
• In memo, Meta says it plans to crack down on employee token use as AI costs soar - The Information